Medical Device News Magazine

Avenda Health Adds Tech Luminary to Board of Directors and Expands Leadership Team

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Avenda Health, an AI healthcare company creating the future of prostate cancer care, today announced the addition of Dr. Ronald D. Sugar to its Board of Directors.  Dr. Sugar also serves as a board member at Apple, Amgen, Chevron, and chairman of Uber as well as the former chairman and CEO of Northrop Grumman.

“We’re thrilled to have Dr. Sugar on our team, and his experience at the intersection of healthcare and technology will be invaluable in our pursuit to provide better care for the millions of men with prostate cancer,” said Shyam Natarajan, co-founder, and CEO of Avenda Health.

Avenda Health’s technology, iQuest, uses deep learning to map an individual’s prostate cancer. This software, not yet cleared by the FDA, provides physicians with a better understanding of the extent of the disease and supports decision-making in cancer care. In a retrospective study of 50 patients presented at the 2022 American Urological Association annual meeting, iQuest improved tumor encapsulation1 over conventional treatment planning from 56 percent to 80 percent2.

“Avenda Health’s AI platform is going to solve a huge unmet need for prostate cancer care. They are on the verge of something transformational,” said Dr. Sugar.

In preparation for the launch of iQuest, the company also added two key executive hires including Carolyn Reul, who will serve as Vice President of Sales and Marketing, and Jemima Escamilla, Ph.D. who will serve as Vice President of Business Development and Growth. Carolyn Reul has over 25 years of experience leading sales, marketing, and product and business development within the medical imaging industry.

Dr. Sugar previously worked for Hitachi Healthcare Americas, where she was the executive director of ultrasound sales. Prior to Hitachi, Reul served as the director of marketing for BK Medical.

Dr. Jemima Escamilla comes from RCT Ventures where she performed in-depth market analysis, and technical, and financial diligence for medical devices. She previously led business and product development at Option3, a MedTech incubator, where she was Principal. Dr. Escamilla holds a doctoral degree in prostate cancer biology.

Avenda Health is creating a more personalized future of prostate cancer care.  Using deep learning, Avenda Health software maps a patient’s cancer in 3D, giving physicians precise information and the confidence to make care decisions.  Dedicated to bringing this cutting-edge technology to all practices and physicians treating prostate cancer patients, Avenda Health aims to improve outcomes, preserve the quality of life, and create a new standard of cancer care.<

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”